Tumor-infiltrating B cells that express high levels of CD5+ have been shown to promote tumor angiogenesis/growth through lymphotoxin production and have been associated with poorer clinical outcomes in HCC (113). The gene discussed is CD5; the disease is hepatocellular carcinoma.